Milestone Pharmaceuticals
MIST
19 hedge funds and large institutions have $17M invested in Milestone Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 8 closing their positions.
21.16% less ownership
Funds ownership: 58.8% → 37.64% (-21%)
24% less funds holding
Funds holding: 25 → 19 (-6)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
93% less capital invested
Capital invested by funds: $231M → $17M (-$214M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$6.18M |
| 2 |
Millennium Management
New York
|
+$2.81M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.18M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$234K |
| 5 |
BlackRock
New York
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.61M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$9.23M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$8.14M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$6.13M |
MIST Hedge Fund Activity: Q1 2020 in Review
19 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2020, worth a combined $17M — down 93% from $231M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MIST and 4 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was RTW Investments, adding an estimated $6.18M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.2M.
- 19 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2020, down from 25 in Q4 2019.
- Funds reported $17M of Milestone Pharmaceuticals stock for Q1 2020, down 93% quarter-over-quarter.
- 4 funds opened new Milestone Pharmaceuticals positions in Q1 2020 and 8 closed out, a net change of -4 holders.
- The largest Milestone Pharmaceuticals buyer in Q1 2020 was RTW Investments, an estimated $6.18M added.
- The largest Milestone Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $12.2M sold.
Based on aggregated 13F filings for Q1 2020.